Synergistic Action of Heat-Shock Protein-90 Inhibitor NVP-AUY922 with Histone Deacetylase Inhibition

被引：0
|
作者：
Kaiser, M. [1 ]
Lamottke, B. [1 ]
Jensen, M. R. [2 ]
Quadt, C. [3 ]
Garcia-Echeverria, C. [3 ]
Mieth, M. [1 ]
Heider, U. [1 ]
Sezer, O. [1 ]
机构：
[1] Charite Univ Med Berlin, D-13353 Berlin, Germany
[2] Novartis Inst BioMed Res, Basel, Switzerland
[3] Novartis Pharma AG, Early Clin Dev, Basel, Switzerland
来源：
CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷
关键词：
D O I：
10.1016/S1557-9190(11)70721-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [31] Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel HSP90 inhibitor
    Raynaud, Florence I.
    Hayes, Angela
    Martins, Vanessa
    Smith, Nicola F.
    Sharp, Swee Y.
    Valenti, Melanie
    Henley, Alan
    Matthews, Thomas P.
    Cheung, Kwai-Ming
    Kalusa, Andrew
    Jones, Keith
    James, Karen
    McDonald, Edward
    Brough, Paul A.
    Massey, Andrew
    Dymock, Brian
    Drysdale, Martin
    Eccles, Suzanne A.
    Workman, Paul
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3524S - 3524S
  • [32] Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer
    Bao, Xiao-Hong
    Takaoka, Munenori
    Hao, Hui-Fang
    Fukazawa, Takuya
    Yamatsuji, Tomoki
    Sakurama, Kazufumi
    Takigawa, Nagio
    Nakajima, Motowo
    Fujiwara, Toshiyoshi
    Naomoto, Yoshio
    ONCOLOGY REPORTS, 2013, 29 (01) : 45 - 50
  • [33] Antitumor Effect of Novel HSP90 Inhibitor NVP-AUY922 against Oral Squamous Cell Carcinoma
    Okui, Tatsuo
    Shimo, Tsuyoshi
    Hassan, Nur Mohammad Monsur
    Fukazawa, Takuya
    Kurio, Naito
    Takaoka, Munenori
    Naomoto, Yoshio
    Sasaki, Akira
    ANTICANCER RESEARCH, 2011, 31 (04) : 1197 - 1204
  • [34] Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922
    Bergstrom, Mats
    Monazzam, Azita
    Razifar, Pasha
    Ide, Susan
    Josephsson, Raymond
    Langstrom, Bengt
    JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (07) : 1204 - 1210
  • [35] Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia
    Djuzenova, Cholpon S.
    Blassl, Christina
    Roloff, Konstanze
    Kuger, Sebastian
    Katzer, Astrid
    Niewidok, Natalia
    Guenther, Nadine
    Polat, Buelent
    Sukhorukov, Vladimir L.
    Flentje, Michael
    CANCER BIOLOGY & THERAPY, 2012, 13 (06) : 425 - 434
  • [36] Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90αRadiosensibilisierender Effekt des neuartigen Hsp90-Inhibitors NVP-AUY922 in Hsp90α-inhibierten humanen Tumorzelllinien
    L. Stingl
    N. Niewidok
    N. Müller
    M. Selle
    C.S. Djuzenova
    M. Flentje
    Strahlentherapie und Onkologie, 2012, 188 (6) : 507 - 517
  • [37] The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization
    Armstrong, Heather
    Butler, Lisa
    Selth, Luke
    Tarulli, Gerard
    Centenera, Margaret
    BJU INTERNATIONAL, 2015, 116 : 39 - 39
  • [38] Pharmakokinetic/phamacodynamic relationship in human xenograft models and PBMC's treated with the Hsp90 inhibitor NVP-AUY922
    Jensen, M. R.
    Ide, S.
    Brueggen, J.
    Schoepfer, J.
    Motwani, M.
    Wang, X.
    Radimerski, T.
    Quadt, C.
    Garcia-Echeverria, C.
    Chene, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 50 - 50
  • [39] THE INFLUENCE OF THE HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR, NVP-AUY922, AND HYPOXIA ON THE EXPRESSION OF HIF-1α AND HIF-2α IN TWO HEAD AND NECK CANCER CELL LINES
    Bayer, C.
    Schilling, D.
    Multhoff, G.
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 : S119 - S119
  • [40] Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α
    Stingl, L.
    Niewidok, N.
    Mueller, N.
    Selle, M.
    Djuzenova, C. S.
    Flentje, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (06) : 507 - 515
12345